Embed Size (px)
DESCRIPTION
Renub Research has announced the addition of the "Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” report to its offering Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide - Market Overview Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-stage cirrhosis and liver cancer.
Citation preview
Renub Research www.renub.com
Hepatitis C Drugs – Market & Forecast
from 2010 to 2018
Source: Given in the report
Global – Forecast for Hepatitis C Drug Market (Million US$), 2013 – 2018
Renub Research www.renub.com
Order the report & get - Hepatitis C Market &
Forecast, HCV Drugs Clinical Trials, Hepatitis C
Pipeline Drugs Sales & Forecast - Worldwide
A comprehensive 164 page report,
supported by data-rich 25 Figures and 2
Tables
Renub Research www.renub.com
Data Available for –Pegasys, Pegintron, Incivek,
Victrelis Sales & Forecast from 2005 to 2018
Source: Given in the report
Global – Pegasys Sales (Million US$), 2005 – 2012
Renub Research www.renub.com
The Following Pipeline Drugs Clinical Trials (Drugs in Phase III) covered in the report
• Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)
• Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)
• Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)
• Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)
• Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)
• BI-207127 (Company: Boerhinger Ingelheim)
• ABT-267 (Company: Abbott Laboratories)
• ABT-072/333 (Company: Abbott Laboratories)
• Alisporivir (Company: Novartis)
Renub Research www.renub.com
The Following Pipeline Drugs Clinical Trials (Drugs in Phase II) covered in the report
• Mericitabine (RG-7128) (Company: Roche)
• Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)
• GS-9256 (Company: Gilead Sciences)
• MK-5172 (Company: Merck)
• Sovaprevir (ACH-1625) (Company: Achillion)
• IDX-320 (Company: Idenix)
• MK-8742 (Company: Merck)
• IDX-719 (Company: Idenix)
• Setrobuvir (ANA-598) (Company: Roche)
• GS-9669 (Company: Gilead Sciences )
• GS-9190 (Tegobuvir) (Company: Gilead Sciences)
• BMS-791325 (Company: Bristol-Myers Squibb)
Renub Research www.renub.com
The following pipeline drugs sales covered in the report :
Simeprevir (TMC 435), Faldaprevir (BI 201335), Asunaprevir (BMS-
650032), Sofosbuvir (PSI-7977 or GS-7977) from 2014 to 2018
Source: Given in the report
Global – Forecast for Simeprevir (TMC 435) Sales (Million US$), 2014 – 2018
Renub Research www.renub.com
The following pipeline drugs sales covered in the report :
Daclatasvir (BMS-790052), ABT-450/r (Ritonavir), ABT-
072/333, Alisporivir, Danoprevir (RG7227), GS-9256, VX-222
from 2014 to 2018
Source: Given in the report
Global – Forecast for Daclatasvir (BMS-790052) Sales (Million US$), 2014 – 2018
Renub Research www.renub.com
Order Form Scan and e-mail this page to [email protected], alternatively one
can also write the Contact Information in an e-mail and mail it.
Else you can also fax this form to +91-120-424-9780
Questions? Please call
+1-678-302-0700 (USA)
+91-120-421-9822 (India), ,+91-120-424-9780
or mail to [email protected]
Renub Research www.renub.com
Format
Report Title: Hepatitis C Market & Forecast, HCV Drugs Clinical
Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide For More Details:
http://www.renub.com/report/hepatitis-c-market-forecast-hcv-
drugs-clinical-trials-hepatitis-c-pipeline-drugs-sales-forecast---
worldwide-118
Single User
(Email from
Publisher)
Hard Copy
(Mail Delivery)
CD – Rom
(Mail Delivery)
Global Site License
(Multiple User
License)
US$ 1,290 US$ 1,440 US$ 1,390 US$ 2,090
Renub Research www.renub.com
For ordering this report: Three easy ways to
place your order
1) Order online by Credit Card (Visa, MasterCard, etc.):
http://www.renub.com/buyreport/118-1454
2) Order by Wire Transfer:
http://www.renub.com/report/wiretransfer.aspx?id=118&pid=1454
To pay by Wire Transfer, please, fill in your contact details in the
form below:
Renub Research www.renub.com
Bank Details
Account Name: Renub Research
A/C No.: 109102000023296
Name of Bank: IDBI Bank Ltd.
Swift Code: IBKLINBB010
Bank Address: 4th Floor
Indian Red Cross Building
1 Red Cross Road
Opposite Parliament Street
New Delhi – 110001
India
Renub Research www.renub.com
Contact Information
First Name: Last Name: Email: Job Title: Company: Address: City: Postal/Zip Code: Country: Phone: Mobile: Fax: Report Format: Your message:
Renub Research www.renub.com
Order by Check
Please post the check accompanied by this form, to:
Company Address: Renub Research
1st Floor,
C-86, Sector-10
Noida - 201301
Uttar Pradesh
India
Phone: +91-120-421-9822, 424-9780
For free Sample copy report or to view any of our sample work please contact us at
[email protected] or call +91-120-421-9822 (India), +1-678-302-0700 (USA)
![chemical safety and biosafety.ppt [Read-Only] Biosafety/chemical s… · HIV, HCV & HBV What is the risk? Hepatitis B (HBV) Hepatitis C ((((HCV)HCV) HIV Estimated new cases each yr](https://img.dokumen.tips/doc/110x75/6062e4a89c535e1fd02cd5a5/chemical-safety-and-read-only-biosafetychemical-s-hiv-hcv-hbv-what-is.jpg)
